Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by jdstoxon Sep 07, 2017 4:38pm
167 Views
Post# 26668722

RE:RE:RE: proprietary xB3 BBB drug delivery tech

RE:RE:RE: proprietary xB3 BBB drug delivery techThis post may be a confession of sorts, and it is meant to answer BearDownAZ's question about why xB3 was not more fully explained by the company, and because this is a confession (of sorts), nobody else is supposed to read this.

I'm not saying it's so, but it may be true, that the mention of xB3 in today's press release was a bit of a slipup, that it may have been accidently included in a quote from one of the members of our new SAB, and may not have been noticed before release.

There may be an upcoming PR where this will be (or would have been) described more fully, an explanation that, in any event, would be (or would have been) substantially the same as my own (explanation).

About superscripting the 3 in xB3, I first typed "xB3 is" into MS Word and superscripted the number 3 so that I had this,  "xB3 is". Then I copied "xB3 is" to the clipboard and pasted it into my SH post, whereupon I reduced the size of the "3" slightly so that it looked better. Then I used it at will, replacing the "is" as required, always leaving a properly formatted space after the 3. If you backspace to the superscripted 3, and get rid of the normally formatted space, then everything you type after the 3 will be superscripted.

I maintain a Word file with such all-purpose constructs, including, but not limited to, xB3 and  jdstox.

jd

Bullboard Posts